Temporomandibular inflammation regulates the matrix metalloproteinases MMP-2 and MMP-9 in limbic structures

Glauce C Nascimento1,2, Bruna B De Paula1, Raquel F Gerlach2

  • 1Department of Psychology, Faculty of Philosophy, Science and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Insights

This study shows that matrix metalloproteinases (MMPs) in the brain

Area of Science:

  • Neuroscience
  • Pain Research
  • Biochemistry

Background:

  • Temporomandibular disorder (TMD) involves orofacial pain, potentially linked to inflammation and emotional issues.
  • Neuroinflammation, involving inflammatory products and glial cells, plays a role in persistent pain.
  • Matrix metalloproteinases (MMPs) are implicated in extracellular matrix remodeling and neuronal function.

Purpose of the Study:

  • To investigate the role of limbic structures in matrix metalloproteinases (MMPs) expression and activity during temporomandibular inflammation-induced orofacial pain.
  • To assess the impact of inflammation on MMP-2 and MMP-9 in specific brain regions.
  • To explore the relationship between glial activation and MMPs in persistent orofacial pain.

Main Methods:

  • Induction of temporomandibular joint (TMJ) inflammation in rats using Complete Freund's Adjuvant (CFA).
  • Assessment of MMP-2 and MMP-9 activity and expression using zymography techniques.
  • Immunofluorescence staining to evaluate glial colocalization with MMPs in limbic structures.

Main Results:

  • CFA-induced TMJ inflammation caused short- and long-term alterations in MMP-2 and MMP-9 expression in limbic areas.
  • Increased gelatinolytic activity of MMPs was observed in the central amygdala, hippocampus, hypothalamus, and midbrain PAG.
  • Enhanced colocalization of MMP-2/GFAP and MMP-9/GFAP indicated glial activation in pain-related brain regions.

Conclusions:

  • Glial activation contributes to gelatinase production in persistent orofacial pain.
  • MMPs and associated glial responses are involved in the initiation and maintenance of TMD-related pain.
  • Inhibition of MMPs presents a potential therapeutic target for managing TMD.